Alleviant Medical Secures $90 Million Financing to Expand Interventional Heart Failure Pivotal Trial Program
Gilde Healthcare leads new round of financing as Alleviant expands focus to the full spectrum of chronic heart failure
AUSTIN, Texas–(BUSINESS WIRE)–Alleviant Medical, Inc., a privately held medical device company developing a no-implant atrial shunt for heart failure, today announced a $90 million financing to fund its second pivotal trial. Led by Gilde Healthcare, the round also adds Omega Funds and includes participation from existing shareholders S3 Ventures, RiverVest Venture Partners, Vensana Capital, Longview Ventures, Gilmartin Capital, TMC Venture Fund, and undisclosed strategic investors. The new pivotal trial, ALLAY-HFrEF, will be the first prospective sham-controlled trial focused on patients with heart failure and reduced ejection fraction (HFrEF) in the atrial shunt space.
